| Trial # | Type | Study Status | Status Date | Title |
|---|
| Alliance A011202 | Breast Adjuvant | Open Active | 2017-03-17 | Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-03 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| SWOG S1207 | Breast Adjuvant | Open Active | 2018-10-08 | SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| NSABP B-51 | Breast Adjuvant | Open Active | 2017-01-24 | NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304) |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-09-17 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| Alliance A171601 | Breast Advanced | Open Active | 2019-01-14 | Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer |
| NRG-BR002 | Breast Advanced | Open Active | 2018-07-19 | NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| Pharm ODO-TE-B301 | Breast Advanced | Open Active | 2018-07-26 | Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Alliance A011106 | Breast Neoadjuvant | Open Active | 2018-12-10 | Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2018-02-07 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| SWOG S1415CD | CCDR | Open Active | 2017-06-07 | SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER) |
| Pharm CanStem303C | GI Colorectal Advanced | Open Active | 2017-08-03 | Boston BioMedical CanStem303C: A Phase III Study of BBI-608 in Combination with 5 Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) |
| NRG Oncology NRG-GI002 | GI Other | Open Active | 2018-08-22 | NRG Oncology NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| Alliance A081105 | Lung NSCLC Adjuvant | Open Active | 2017-08-25 | Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-12-09 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-12-19 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| ECOG-ACRIN EA5142 | Lung NSCLC Adjuvant | Open Active | 2018-09-17 | ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers |
| NRG Oncology NRG-LU002 | Lung NSCLC Advanced | Open Active | 2018-06-21 | NRG Oncology NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II/III Trial |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2019-02-05 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-G | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-03-11 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| Alliance A011401 | Supportive | Open Active | 2016-09-29 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| UNM 1701 | Supportive | Open Active | 2017-10-12 | INST UNM 1701: A Qualitative Pilot Study to Evaluate the Unmet Needs of Patients Receiving Oral Oncolytic Therapy |
| WFU WF 97115 | Supportive | Open Active | 2018-10-31 | WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-19 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| NSABP B-55/BIG 6-13 | Breast Adjuvant | Open Active | 2018-11-21 | NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy |
| SWOG S1207 | Breast Adjuvant | Open Active | 2018-10-08 | SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-06-01 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| Alliance A171601 | Breast Advanced | Open Active | 2019-01-11 | Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| NRG-BR002 | Breast Advanced | Open Active | 2018-03-01 | NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| Pharm CP-MGAH22-04 | Breast Advanced | Open Active | 2018-02-16 | MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2019-01-11 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| Alliance A021502 | GI Colorectal Adjuvant | Open Active | 2018-10-12 | Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| SWOG S1613 | GI Colorectal Advanced | Open Active | 2018-02-23 | SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification |
| SWOG S0820 | GI Colorectal Prevention | Open Active | 2018-07-27 | SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| INST 96144 | Ill Defined | Open Active | 2015-07-28 | INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| Alliance A081105 | Lung NSCLC Adjuvant | Open Active | 2017-08-25 | Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-12 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-05-12 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| ECOG-ACRIN EA5142 | Lung NSCLC Adjuvant | Open Active | 2018-09-07 | ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers |
| NRG Oncology NRG-LU002 | Lung NSCLC Advanced | Open Active | 2018-02-28 | NRG Oncology NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II/III Trial |
| SWOG S1400F | Lung SCLC Advanced | Open Active | 2018-08-18 | SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY) |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2018-02-23 | ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
| SWOG S1616 | Skin Melanoma Advanced | Open Active | 2018-09-24 | SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2019-02-05 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-03-11 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| Alliance A011401 | Supportive | Open Active | 2016-09-17 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| DCP-001 | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-04 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| NSABP B-51 | Breast Adjuvant | Open Active | 2017-01-26 | NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304) |
| SWOG S1207 | Breast Adjuvant | Open Active | 2018-10-08 | SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-06-01 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| Pharm CP-MGAH22-04 | Breast Advanced | Open Active | 2018-02-16 | MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment |
| Pharm ODO-TE-B301 | Breast Advanced | Open Active | 2018-07-26 | Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane |
| RTOG 1119 | Breast Advanced | Open Active | 2016-10-06 | RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-08-21 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| Pharm CanStem303C | GI Colorectal Advanced | Open Active | 2017-08-03 | Boston BioMedical CanStem303C: A Phase III Study of BBI-608 in Combination with 5 Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) |
| SWOG S1613 | GI Colorectal Advanced | Open Active | 2018-02-15 | SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| RTOG 0924 | GU Prostate Advanced | Open Active | 2015-08-04 | RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2011-02-07 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| NRG Oncology NRG-GY005 | GYN Other | Open Active | 2019-02-08 | NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) |
| Pharm YO39523/GOG-3015 | GYN Other | Open Active | 2018-05-14 | Hoffman La Roche YO39523/GOG-3015: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atexolizumab versus Placebo in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly Diagnosed Stage III/IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2017-03-27 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| ECOG-ACRIN EA5142 | Lung NSCLC Adjuvant | Open Active | 2018-09-07 | ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers |
| SWOG S1400F | Lung SCLC Advanced | Open Active | 2018-08-18 | SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY) |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2017-04-26 | ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2019-02-05 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-G | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-03-11 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| Alliance A011401 | Supportive | Open Active | 2016-12-16 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| DCP-001 | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| ECOG-ACRIN E1Q11 | Supportive | Open Active | 2018-04-18 | ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-04 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| NSABP B-51 | Breast Adjuvant | Open Active | 2016-10-20 | NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304) |
| SWOG S1207 | Breast Adjuvant | Open Active | 2018-10-08 | SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-06-01 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| Alliance A221505 | Breast Advanced | Open Active | 2018-04-10 | Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| NRG-BR002 | Breast Advanced | Open Active | 2017-05-04 | NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| Pharm CP-MGAH22-04 | Breast Advanced | Open Active | 2018-02-16 | MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment |
| Pharm ODO-TE-B301 | Breast Advanced | Open Active | 2018-07-26 | Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Alliance A011106 | Breast Neoadjuvant | Open Active | 2018-12-10 | Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-11-05 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| Pharm CanStem303C | GI Colorectal Advanced | Open Active | 2017-08-03 | Boston BioMedical CanStem303C: A Phase III Study of BBI-608 in Combination with 5 Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) |
| SWOG S1613 | GI Colorectal Advanced | Open Active | 2018-02-22 | SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification |
| SWOG S0820 | GI Colorectal Prevention | Open Active | 2018-09-14 | SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| Alliance A021602 | GI Other | Open Active | 2018-10-18 | Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) |
| NRG Oncology NRG-GI002 | GI Other | Open Active | 2018-11-15 | NRG Oncology NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer |
| Pharm PrTK03 | GU Prostate Adjuvant | Open Active | 2017-06-28 | Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| NRG Oncology NRG-GU005 | GU Prostate Advanced | Open Active | 2018-01-29 | NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer |
| ECOG-ACRIN EA3132 | Head And Neck Adjuvant | Open Active | 2016-10-26 | ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Pharm 689-03 | Head And Neck Advanced | Open Active | 2019-02-08 | Merck 689-03: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy forStage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) |
| Pharm INCB 18424-MA-GD-301 | Hematology Stem Cell Transplant | Open Active | 2019-01-29 | Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant |
| INST 96144 | Ill Defined | Open Active | 2014-12-09 | INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| Alliance A081105 | Lung NSCLC Adjuvant | Open Active | 2017-08-25 | Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-17 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-05-17 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| SWOG S1400F | Lung SCLC Advanced | Open Active | 2018-08-18 | SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY) |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2017-04-26 | ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2019-02-05 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-G | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-03-11 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-08 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-06-01 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| Alliance A171601 | Breast Advanced | Open Active | 2019-01-11 | Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| INST 1302 | Breast Advanced | Open Active | 2013-04-02 | INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study) |
| Pharm ODO-TE-B301 | Breast Advanced | Open Active | 2018-07-26 | Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Alliance A011106 | Breast Neoadjuvant | Open Active | 2018-12-10 | Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study |
| SWOG S1415CD | CCDR | Open Active | 2017-06-07 | SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER) |
| SWOG S0820 | GI Colorectal Prevention | Open Active | 2017-11-29 | SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| Pharm CA209901 | GU Other | Open Active | 2017-08-30 | Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer |
| Pharm GU14-188 | GU Other | Open Active | 2018-03-13 | Hoosier Cancer Research Network GU14-188: Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer: HCRN GU14-188 |
| INST 96144 | Ill Defined | Open Active | 2013-06-04 | INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| Alliance A081105 | Lung NSCLC Adjuvant | Open Active | 2017-08-25 | Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| ECOG-ACRIN EA5142 | Lung NSCLC Adjuvant | Open Active | 2018-09-07 | ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2017-04-26 | ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2019-02-05 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-G | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-04-17 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| Alliance A011401 | Supportive | Open Active | 2016-11-01 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| ECOG-ACRIN EAF151 | Brain Advanced | Open Active | 2017-08-30 | ECOG-ACRIN EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma |
| Diffusion 100-206 | Brain Advanced | Open Active | 2018-05-22 | Diffusion Pharmaceuticals 100-206: Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects |
| NRG Oncology NRG-BN003 | Brain Other | Open Active | 2017-10-20 | NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma |
| NCCTG N0577 | Brain Advanced | Open Active | 2017-12-18 | NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma |
| INST 1409 | Brain Advanced | Open Active | 2016-03-09 | INST 1409: Single Center, Phase II Study of Whole Brain Radiation Using IMRT to Spare the Hippocampus while Delivering Differential Doses to Subclinical Sites versus Gross Disease for Treatment of Patients with Brain Metastases |
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-03 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| Alliance A011202 | Breast Adjuvant | Open Active | 2016-03-02 | Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2019-01-15 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| Dune Medical Devices CP-07-001 | Breast Adjuvant | Open Active | 2018-03-09 | Dune Medical Devices CP-07-001: MarginProbe System U.S. Post-Approval Study |
| NSABP B-55/BIG 6-13 | Breast Adjuvant | Open Active | 2018-11-21 | NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy |
| NSABP B-51 | Breast Adjuvant | Open Active | 2016-08-01 | NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304) |
| Alliance A171601 | Breast Advanced | Open Active | 2019-01-11 | Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-06-01 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| SWOG S1207 | Breast Adjuvant | Open Active | 2018-10-08 | SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-03-28 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| Alliance A221505 | Breast Advanced | Open Active | 2018-04-10 | Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction |
| Novartis CBYL719X2402 | Breast Advanced | Open Active | 2017-11-08 | Novartis CBYL719X2402: A Phase II, Multicenter, Open-label, Two-cohort, NoncomparativeStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), who have Progressed on or after CDK 4/6 Inhibitor Treatment |
| NRG-BR002 | Breast Advanced | Open Active | 2016-04-07 | NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| INST 1302 | Breast Advanced | Open Active | 2013-04-02 | INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study) |
| Pharm ODO-TE-B301 | Breast Advanced | Open Active | 2018-07-26 | Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane |
| Pharm CP-MGAH22-04 | Breast Advanced | Open Active | 2017-11-07 | MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment |
| Pharm SGNLVA-002 | Breast Advanced | Open Active | 2018-02-20 | Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer |
| Pharm SGNLVA-001 | Breast Advanced | Open Active | 2017-09-26 | Seattle Genetics, Inc. SGNLVA-001: A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of SGN-LIVIA in Patients with LIV-1-Positive Metastatic Breast Cancer |
| RTOG 1119 | Breast Advanced | Open Active | 2016-10-06 | RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer |
| Pharm WO40181 | Breast Advanced | Open Active | 2018-10-25 | Genentech WO40181: A Phase II, Multicenter, Randomized Study to Compare the Efficacy of Venetoclax Plus Fulvestrant Versus Fulvestrant in Women with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer who Experienced Disease Recurrence or Progression During or After CDK4/6 Inhibitor Therapy |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-09-05 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| Alliance A011106 | Breast Neoadjuvant | Open Active | 2018-12-10 | Alliance A011106: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| UNM 1607 | Breast Neoadjuvant | Open Active | 2018-04-16 | INST UNM 1607: Monitoring of Breast Cancer Therapy Using High-speed MR Spectroscopic Imaging |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2019-01-11 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| ECOG-ACRIN EA1151 | Breast Other | Open Active | 2018-08-31 | ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST) |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2018-02-07 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| Alliance A221405/ IBCSG 48-14/ BIG 8-13 | Breast Other | Open Active | 2016-10-13 | Alliance A221405, IBCSG 48-14, BIG 8-13: POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer |
| UNM 1525 | Breast Prevention | Open Active | 2016-09-22 | INST UNM 1525: Breast cancer screening among medically underserved women in New Mexico: Comparing outcomes and LOwering recall rates with digital breast tomosynthesis (3D mammography) VErsus full-field digital (2D) mammography. The LOVE New Mexico study) |
| SWOG S1703 | Breast Other | Open Active | 2019-01-30 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| WFU WF-30917CD | CCDR | Open Active | 2018-10-19 | WFU WF-30917CD: A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors |
| SWOG S1415CD | CCDR | Open Active | 2017-06-07 | SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER) |
| Alliance A191402CD | CCDR | Open Active | 2018-01-24 | Alliance A191402CD: Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men |
| UNM 1528 | Epidemiological | Open Active | 2016-04-01 | INST UNM 1528: Improving Colorectal Cancer Screening Rates in New Mexico Hispanics through Community Partnerships and Implementation Science |
| CIBMTR Protocol for a Research Database | Epidemiological | Open Active | 2017-06-29 | CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
| UNM 1614 | Epidemiological | Open Active | 2017-04-23 | INST UNM 1614: Cost Measurement Feasibility for Low-Income Cancer Patients |
| UNM 1608 | Epidemiological | Open Active | 2017-10-01 | INST UNM 1608: Comparative Effectiveness of Interventions to Increase Guideline-based Genetic Counseling in Ethnically and Geographically Diverse Cancer Survivors |
| Alliance A021502 | GI Colorectal Adjuvant | Open Active | 2018-10-12 | Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| UNM 1803 | Epidemiological | Open Active | 2018-06-26 | INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative |
| INST 1204 | GI Colorectal Ancillary | Open Active | 2012-05-22 | INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer |
| SWOG S1613 | GI Colorectal Advanced | Open Active | 2018-02-15 | SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification |
| Pharm CanStem303C | GI Colorectal Advanced | Open Active | 2017-06-26 | Boston BioMedical CanStem303C: A Phase III Study of BBI-608 in Combination with 5 Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) |
| SWOG S0820 | GI Colorectal Prevention | Open Active | 2017-10-05 | SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| INST UNM 1809 | GI Colorectal Prevention | Open Active | 2018-12-27 | INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States |
| NRG Oncology NRG-GI002 | GI Other | Open Active | 2018-08-22 | NRG Oncology NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer |
| Alliance A021602 | GI Other | Open Active | 2018-10-18 | Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) |
| Pharm CA209901 | GU Other | Open Active | 2017-08-30 | Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer |
| Alliance A021501 | GI Pancreatic Neoadjuvant | Open Active | 2018-11-30 | Alliance A021501: Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas |
| UNM 1603 | GI Other | Open Active | 2016-11-30 | INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health |
| Pharm GU14-188 | GU Other | Open Active | 2018-02-07 | Hoosier Cancer Research Network GU14-188: Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer: HCRN GU14-188 |
| Pharm CO-338-085 | GU Other | Open Active | 2018-10-05 | Clovis Oncology CO-338-085: ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| Pharm PrTK03 | GU Prostate Adjuvant | Open Active | 2017-06-28 | Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer |
| Pharm MK-3475-564-00 | GU RenalCell Adjuvant | Open Active | 2017-11-21 | Merck MK-3475-564-00: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) |
| Pharm 1205-201 | GU Prostate Advanced | Open Active | 2018-08-01 | Constellation Pharmaceuticals 1205-201: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer |
| NRG Oncology NRG-GU005 | GU Prostate Advanced | Open Active | 2018-01-29 | NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer |
| RTOG 0724/GOG-0724 | GYN Cervical Adjuvant | Open Active | 2015-07-23 | RTOG 0724/GOG-0724 : Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2010-10-20 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| NRG Oncology NRG-GY005 | GYN Other | Open Active | 2019-02-08 | NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) |
| Pharm GCT1015-04 | GYN Cervical Advanced | Open Active | 2019-02-07 | Genmab GCT1015-04: A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax -TF-ADC) Therapy in Previously Treated, Recurrent or Metastatic Cervical Cancer |
| NRG Oncology NRG-GY006 | GYN Cervical Advanced | Open Active | 2018-03-13 | NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA VaginalCancer |
| UNM 1509 | GYN Other | Open Active | 2015-12-02 | INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies |
| Pharm YO39523/GOG-3015 | GYN Other | Open Active | 2017-10-02 | Hoffman La Roche YO39523/GOG-3015: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atexolizumab versus Placebo in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly Diagnosed Stage III/IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NRG Oncology NRG-GY007 | GYN Ovarian Advanced | Open Active | 2018-12-17 | NRG Oncology NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| GOG 0264 | GYN Ovarian Advanced | Open Active | 2011-04-21 | GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary |
| UNM 1419 | GYN Ovarian Advanced | Open Active | 2018-11-12 | INST 1419: A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers with Advanced or Recurrent Ovarian Cancer |
| NRG-GY009 | GYN Ovarian Advanced | Open Active | 2018-08-28 | NRG Oncology NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubican and CTEP-Supplied Atezolizumab (IND #134427) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicine/Bevacizumab in Platinum Resistant Ovarian Cancer |
| NRG Oncology NRG-GY016 | GYN Ovarian Advanced | Open Active | 2019-02-06 | NRG Oncology NRG-GY016: A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary |
| ECOG-ACRIN EA3132 | Head And Neck Adjuvant | Open Active | 2016-12-14 | ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| GOG 0238 | GYN Uterine Advanced | Open Active | 2015-08-24 | GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus |
| INST 1310 | Head And Neck Advanced | Open Active | 2015-02-25 | INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma |
| INST 1008 | Head And Neck Advanced | Open Active | 2014-12-11 | INST 1008: Expression and Epigenetic Silencing of MicroRNA for Predicting the Therapeutic Response and Prognosis of HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) |
| RTOG 1008 | Head And Neck Adjuvant | Open Active | 2017-01-13 | RTOG 1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors |
| Pharm ImmunoGen 0601 | Hematology Acute Leukemia | Open Active | 2018-05-07 | ImmunoGen 0601: A Phase I, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD-33-positive Acute Myeloid Leukemia |
| Pharm 689-03 | Head And Neck Advanced | Open Active | 2019-01-11 | Merck 689-03: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy forStage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) |
| UNM 1512CR | Hematology Acute Leukemia | Open Active | 2018-05-23 | INST UNM 1512 (CHART REVIEW): A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS |
| UNM 1503 | Hematology Acute Leukemia | Open Active | 2016-07-28 | INST UNM 1503: Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses |
| Alliance A061202 | Hematology Myeloma | Open Active | 2018-10-03 | Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy |
| SWOG S1608 | Hematology Lymphoma Non-Hodgkins | Open Active | 2018-10-08 | SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma |
| Pharm GO29365 | Hematology Lymphoma Non-Hodgkins | Open Active | 2018-11-08 | Genentech GO29365: A Phase IB/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCD S4501A) in Combination with Rituximab (R) or Obinutuxumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma |
| INST H-25667 | Hematology Other | Open Active | 2012-08-25 | INST H-25667: The Molecular Basis of Histiocytic Diseases |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2016-10-06 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| Pharm INCB 18424-MA-GD-301 | Hematology Stem Cell Transplant | Open Active | 2019-01-29 | Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant |
| Pharm INCB 39110-209 | Hematology Other | Open Active | 2018-05-17 | Incyte INCB 39110-209: An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis |
| INST 1306 | Ill Defined | Open Active | 2015-01-01 | INST 1306: Whole Genome Sequencing of Human Cancer Tissues |
| INST 1101 | Ill Defined | Open Active | 2011-03-30 | INST 1101: Investigating Cancer-Related Information Processing of Patients and Family Members |
| Alliance A081105 | Lung NSCLC Adjuvant | Open Active | 2017-08-25 | Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| SWOG S1316 | Ill Defined | Open Active | 2018-06-21 | SWOG S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-05-09 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-09 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| NRG Oncology NRG-LU002 | Lung NSCLC Advanced | Open Active | 2017-12-06 | NRG Oncology NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II/III Trial |
| ECOG-ACRIN EA5142 | Lung NSCLC Adjuvant | Open Active | 2018-09-07 | ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers |
| NRG Oncology NRG-CC003 | Lung SCLC Adjuvant | Open Active | 2019-01-09 | NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer |
| CALGB 30610 | Lung SCLC Adjuvant | Open Active | 2013-10-29 | CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2017-04-26 | ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
| SWOG S1400F | Lung SCLC Advanced | Open Active | 2018-08-18 | SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY) |
| SWOG S1616 | Skin Melanoma Advanced | Open Active | 2018-09-24 | SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent |
| Pharm TLPLDC | Skin Melanoma Advanced | Open Active | 2017-04-04 | Cancer Insight TLPLDC: A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (resected) Melanoma to Prevent Recurrence |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2019-02-05 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-03-11 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-G | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| Pharm BXQ-350.AA | Solid Tumors Other | Open Active | 2016-11-30 | Bexion BXQ-350.AA: Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients with Advanced Solid Tumors and Recurrent High-Grade Gliomas |
| Pharm 2455-001 | Solid Tumors Other | Open Active | 2018-03-06 | Kyowa Kirin Pharmaceutical 2455-001: Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors |
| Pharm RGX-104-001 | Solid Tumors Other | Open Active | 2019-01-10 | Rgenix RGX-104-001: A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, With or Without Nivolumab in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies |
| Pharm R3767-ONC-1613 | Solid Tumors Other | Open Active | 2017-12-15 | Regeneron Pharmaceuticals R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies |
| Pharm NLG-8021 | Solid Tumors Other | Open Active | 2017-09-29 | NewLink Genetics NLG-8021: A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors |
| Pharm TRX518-003 | Solid Tumors Other | Open Active | 2016-09-28 | Leap Therapeutics. Inc TRX518-003: A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults with Advanced Solid Tumors |
| Pharm TPU-TAS-120-101 | Solid Tumors Other | Open Active | 2017-07-10 | Taiho Oncology, Inc. TPU-TAS-120-101: A Dose-finding Phase 1 Study TAS-120 in Patients with Advanced Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors |
| Alliance Foundation Trials AFT-28 | Supportive | Open Active | 2018-09-12 | Alliance Foundation Trials AFT-28: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) |
| Alliance A011401 | Supportive | Open Active | 2016-10-02 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| DCP-002 | Supportive | Open Active | 2017-11-16 | NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations |
| DCP-001 | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| WFU WF 97115 | Supportive | Open Active | 2017-07-06 | WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer |
| NRG Oncology NRG-CC004 | Supportive | Open Active | 2017-10-12 | NRG Oncology NRG-CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer |
| ECOG-ACRIN E1Q11 | Supportive | Open Active | 2018-04-18 | ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship |
